← SynDRA
lanreotide
SynDRA canonical compound SYN0041796 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | SSTR2 | SSTR3 | SSTR5 |
|---|
| Mechanism of action | somatostatin receptor agonist |
|---|
| Indication | acromegaly |
|---|
| Disease area | endocrinology |
|---|
All known targets
- SSTR2
- SSTR3
- SSTR5
- SSTR1
- SSTR4
- Sstr2
- Sstr3
- Sstr5
Mechanisms of action (all sources)
- somatostatin receptor agonist
- SSTR2 MODULATOR
- SSTR2 AGONIST
- SSTR5 AGONIST
Drug classes
- Somatostatin Receptor Agonists
- Antineoplastic Agents
- Somatostatin Analog
ATC classes
Cross-references
Synonyms
- angiopeptin
- ipstyl
- lanreotide autogel
- somatulin-autogel
- somatuline
- lanreotide acetate
- Lanreotide acetate
- Angiopeptin acetate
- Somatuline
- Somatulin
- DC 13-116
- Autogel
- Bim-23014
- Lanreotide [INN:BAN]
- Lanreotidum [INN-Latin]
- Lanreotida [INN-Spanish]
- Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2
- 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide
- Somatuline lp (TN)
- Lanreotide Autogel
- CHEBI:135901
- GLXC-15339
- H-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2
- L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-arginine
- Lanreotida
- Angiopeptin
- Somatuline autogel
- Somatuline la
- LANREOTIDE ACETATE
- SOMATULINE DEPOT
Look up lanreotide in the interactive SynDRA portal →